Kura Oncology Inc (KURA)
7.78
-0.39
(-4.77%)
USD |
NASDAQ |
Jan 08, 16:00
7.76
-0.02
(-0.26%)
After-Hours: 20:00
Kura Oncology SG&A Expense (Quarterly): 18.18M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | 41.24M |
| AIM ImmunoTech Inc | 3.079M |
| Perspective Therapeutics Inc | 6.975M |
| Protalix BioTherapeutics Inc | 2.595M |
| Armata Pharmaceuticals Inc | 3.244M |